Cargando…

New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment

BACKGROUND: Novel therapeutic strategies are urgently needed for the treatment of metastatic Urothelial Bladder Cancer. DNA damaging repair (DDR) targeting has been introduced in cinical trials for bladder cancer patients that carry alterations in homologous DNA repair genes, letting to envisage sus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Criscuolo, Daniela, Morra, Francesco, Giannella, Riccardo, Visconti, Roberta, Cerrato, Aniello, Celetti, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385418/ https://www.ncbi.nlm.nih.gov/pubmed/30791940 http://dx.doi.org/10.1186/s13046-019-1089-z

Ejemplares similares

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors
por: Criscuolo, Daniela, et al.
Publicado: (2019)

CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer
por: Morra, Francesco, et al.
Publicado: (2019)

Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
por: Cerrato, Aniello, et al.
Publicado: (2016)

NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells
por: Cerrato, Aniello, et al.
Publicado: (2019)

The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells
por: Morra, Francesco, et al.
Publicado: (2017)

The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer
por: Cerrato, Aniello, et al.
Publicado: (2018)

A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options
por: Criscuolo, Daniela, et al.
Publicado: (2022)

The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy
por: Visconti, Roberta, et al.
Publicado: (2017)

CAF-1 Subunits Levels Suggest Combined Treatments with PARP-Inhibitors and Ionizing Radiation in Advanced HNSCC
por: Morra, Francesco, et al.
Publicado: (2019)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma
por: Morra, Francesco, et al.
Publicado: (2022)

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
por: Chu, Yu-Yi, et al.
Publicado: (2022)

Editorial: Combinatorial Approaches for Cancer Treatment: From Basic to Translational Research
por: Cerrato, Aniello, et al.
Publicado: (2022)

FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC
por: Morra, Francesco, et al.
Publicado: (2015)

Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment
por: Thy, Sophia, et al.
Publicado: (2021)

Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models
por: Nguyen, Lily L., et al.
Publicado: (2023)

Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
por: Soung, Young-Hwa, et al.
Publicado: (2023)

Mechanism of PARP inhibitor resistance and potential overcoming strategies
por: Fu, Xiaoyu, et al.
Publicado: (2023)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

Combinatorial Therapy of High Dose Vitamin C and PARP Inhibitors in DNA Repair Deficiency: A Series of 8 Patients
por: Demiray, Mutlu
Publicado: (2020)

Combinatorial targeting of Hippo-STRIPAK and PARP elicits synthetic lethality in gastrointestinal cancers
por: An, Liwei, et al.
Publicado: (2022)

The tumour suppressor CCDC6 is involved in ROS tolerance and neoplastic transformation by evading ferroptosis
por: Morra, Francesco, et al.
Publicado: (2021)

Transcriptomics reveals in vivo efficacy of PARP inhibitor combinatorial synergy with platinum-based chemotherapy in human non-small cell lung carcinoma models
por: Stolzenburg, Lindsay R., et al.
Publicado: (2022)

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
por: Miller, Rowan E, et al.
Publicado: (2022)

PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
por: Barcellini, Amelia, et al.
Publicado: (2021)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

Cost of illness of urothelial bladder cancer in Italy
por: Gerace, Claudio, et al.
Publicado: (2017)

PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy
por: Abecassis, Irina, et al.
Publicado: (2019)

Evidence for Bladder Urothelial Pathophysiology in Functional Bladder Disorders
por: Keay, Susan K., et al.
Publicado: (2014)

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
por: Stenehjem, David D, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
por: Roviello, Giandomenico, et al.
Publicado: (2021)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
por: Maluchenko, Natalya, et al.
Publicado: (2022)

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
por: Nero, Camilla, et al.
Publicado: (2021)

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer
por: Veneziani, Ana C., et al.
Publicado: (2023)

The interplay of extracellular matrix and microbiome in urothelial bladder cancer
por: Alfano, Massimo, et al.
Publicado: (2015)

PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth
por: Bhattacharjee, Sayani, et al.
Publicado: (2022)

Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer
por: Xu, Chao, et al.
Publicado: (2023)

Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology
por: Mweempwa, Angela, et al.
Publicado: (2019)

Intravesical therapy for urothelial carcinoma of the bladder
por: Manoharan, M.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_kpqa4ptsp93jvfjg9k5n2o6ij3